Prellis in the Media 

Prellis Biologics, Inc. Generates 300 Human Antibodies That Bind the SARS-CoV2 Virus; Pursues Development of a Treatment and Preventative Therapy for COVID-19 Infection

Business Wire

Prellis Biologics Pursues Bioprinted Lymph Nodes for Production of COVID-19 Antibodies

3DHEALS Jenny Chen Interviews Gavan Wilhite: 3DHEALS2020 Software Design Interview


On the Road to 3-D Printed Organs

The Scientist

© Prellis Biologics 2020, All rights reserved.